Abstract
Currently, there is no unified consensus on short-term anticoagulation after cardioversion of atrial fibrillation lasting less than 48 h in low-cardioembolic-risk patients. The aim of this study is to evaluate the rate of transient ischemic attacks, stroke and death in this subset of patients after cardioversion without post-procedural anticoagulation. In a prospective observational study, patients with recent-onset AF undergoing cardioversion attempts in the Emergency Department were evaluated over the past 3 years. Inclusion criteria were conversion to sinus rhythm, low thromboembolic risk defined by a CHA2DS2VASc score of 0–1 points for males (0–2 points for females aged over 65 years), and hospital discharge without anticoagulant treatment. Patients with severe valvular heart disease, underlying systemic causes of AF, and those discharged with anticoagulant therapy were excluded. The main outcomes measured were TIA, stroke and death at thirty days' follow-up after discharge. During the study period, 218 successful cardioversions, obtained both electrically and pharmacologically, were performed on 157 patients. One hundred and eleven patients were males (71%), the mean age was 55.2 years (±standard deviation 10.7), 99 patients (63%) reported a CHA2DS2VASc score of 0, and the remaining 58 (37%) had a risk profile of 1 point. Of these, latter 8 were females (5%) older than 65 years (risk score 2 points). At the thirty days outcome, none of the 150 enrolled patients who completed a follow-up visit has reported TIA or stroke, nor died, in the overall 211 successful cardioversions evaluated. In our study, the rate of thromboembolic events after cardioversion of recent-onset AF of less than 48 h duration, in patients with a 0–1 CHA2DS2VASc risk profile (females 0–2), appeared to be extremely low even in absence of post-procedural anticoagulation. These findings seem to confirm data from previous studies, and suggest that routine post-procedural short-term anticoagulation may be considered as an overtreatment in this very low-risk subset of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McDonald AJ, Pelletier AJ et al (2008) Increasing US emergency department visit rates and subsequent hospital admission for atrial fibrillation from 1993 to 2004. Ann Emerg Med 51(1):58–65
Decker WW, Smars PA, Vaidyanathan L et al (2008) A prospective, randomized trial of an emergency department observation unit for acute onset atrial fibrillation. Ann Emerg Med 52:322–328
Michael JA, Stiell IG, Agarwal S, Mandavia DP (1999) Cardioversion of paroxysmal atrial fibrillation in the emergency department. Ann Emerg Med 33:379–387
Burton JH, Vinson DR, Drummond K et al (2004) Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med 44:20–30
Stiell IG, Clement CM, Perry JJ et al (2010) Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 12:181–191
Scheuermeyer XF, Grafstein E, Stenstrom R, Innes G et al (2010) Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter. Acad Emerg Med 17:408–415
Vinson DR, Hoehn T, Graber DJ, Williams TM (2012) Managing emergency department patients with recent onset atrial fibrillation. J Emerg Med 42(2):139–148
You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic Therapy and Prevention of Thrombosis, 9th American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e535S–e575S
Camm AJ, Kirchhof P, Lip GYH et al (2010) Guidelines for the management of atrial fibrillation. The task force for the management of atrial fibrillation of the European society of Cardiology (ESC). Eur Heart J 31:2369–2429
Camm AJ, Lip GYH, De Caterina R et al (2012) Focused Update of the ESC guidelines for the management of atrial fibrillation: an update of 2010 ESC guidelines. Europace. 14:1385–1413
January CT, Wann LS, Alpert JS et al (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:2246–2280
Cristoni L, Tampieri A, Mucci F, Iannone P et al (2011) Cardioversion of acute atrial fibrillation in the short observation unit: comparison of a protocol focused on electrical cardioversion with simple antiarrhythmic treatment. Emerg Med J. 28:932–937
Scheuermeyer XF, Grafstein E, Stenstrom R et al (2012) Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause. Ann Emerg Med 60(6):755–765
Weigner MJ, Caulfield TA, Danias PG et al (1997) Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 126:615–620
Gallagher MM, Hennessy BJ, Edvardsson N et al (2002) Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 40:926–933
Berger M, Schweitzer P (1998) Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 82:1545–1547
Khan IA (2002) Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter. Am Heart J 144(1):11–22
Antonielli E, Pizzuti A, Bassignana A et al (1998) Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. Am J Cardiol 84:1545–1547
Kleemann T, Becker T, Strauss M et al (2009) Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation >48 h undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion. J Am Soc Echocradiogr. 22:1403–1408
Stoddard MF, Dawkins PR, Prince CR et al (1995) Left atrial appendage thrombus is not not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. SJ Am Coll Cardiol 25:452–459
Airaksinen KEJ, Gronberg T, Nuotio I et al (2013) Thromboembolic complications after cardioversion of acute atrial fibrillation. J Am Coll Cardiol 62(13):1187–1192
Van den Ham HA, Klungel OH, Singer DE et al (2015) Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: results From a National Primary Care Database. J Am Coll Cardiol 66(17):1851–1859
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
All procedures performed in this study involving human participants were in accordance with the ethical standards of institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from each patient, in compliance with ethical standards.
Rights and permissions
About this article
Cite this article
Tampieri, A., Cipriano, V., Mucci, F. et al. Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk. Intern Emerg Med 13, 87–93 (2018). https://doi.org/10.1007/s11739-016-1589-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-016-1589-1